GUILFORD — A medical know-how firm based by entrepreneur Dr. Jonathan Rothberg goes to grow to be a publicly-traded firm by way of a $1.46 billion merger.
Rothberg’s firm, Quantum-Si, is merging with HighCape Capital Acquisition Corp., a particular goal acquisition firm. The deal is predicted to shut within the second quarter of this yr.
Particular goal acquisition corporations are shell companies whose sole goal is to take an organization public with out having to undergo a standard preliminary public providing. When the deal closes, Quantum-Si’s inventory will commerce on the Nasdaq inventory market underneath the ticker image QSI
Rothberg will grow to be government chairman of the mixed firm when the deal closes. He stated a part of the objective in taking the corporate public is to “proceed to democratize medication, by growing the sphere of proteomics to make a major affect on drug discovery, educational analysis, and diagnostics.”
Proteomics is the large-scale research of proteins, that are very important elements of dwelling organisms. Utilizing semiconductor to sequence proteins permits for the creation of extra delicate and correct analysis instruments and diagnostics.
“I used to be fortunate sufficient to be concerned within the invention of next-generation DNA sequencing,” Rothberg stated. “So it’s becoming that my staff will convey next-generation protein sequencing to the world. DNA sequencing modified medication and analysis by revealing what might occur within the physique; protein sequencing exhibits what is going on proper now.”